Novacea, Inc. (NASDAQ: NOVC), located in South San Francisco, California, is a biopharmaceutical company focused on in-licensing, developing and commercializing novel therapies for the treatment of cancer. We currently have two clinical-stage oncology product candidates. Our lead product candidate, Asentar™ (DN-101), is part of an exclusive worldwide development and commercialization agreement with Schering Plough Corporation. Asentar is currently in a Phase 3 clinical trial for the treatment of androgen-independent prostate cancer, and a Phase 2 trial for the treatment of advanced pancreatic cancer. Our second product candidate, AQ4N, is being investigated in combination with radiation and chemotherapy in a Phase 1/2 clinical trial of patients with newly diagnosed glioblastoma multiforme and a Phase 2 trial for patients with acute lumphoblastic leukemia.
Our experienced team uses its expertise in oncology product development to identify, license and develop novel therapeutics with the potential to improve clinical outcomes for cancer patients. We believe that our oncology development expertise enables our team to design efficient clinical development and commercialization programs that could provide cancer patients with improved treatment options over current standards of care.
Last Updated: 11-01-2007